NasdaqGM - Nasdaq Real Time Price
USD
Braveheart Bio, Inc. (BRVE)
19.21
+0.61
(+3.28%)
As of 12:04:57 PM EST. Market Open.
Key Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Travis Murdoch B.S., M.D., M.Sc.
|
CEO, President & Director | 482.51k | -- | 1985 |
|
Mr. James Paul Rickey CPA
|
Chief Financial Officer | 455.18k | -- | 1979 |
|
Ms. Michele A. Anderson
|
Chief Development Officer | 474.75k | -- | 1967 |
|
Mr. Marc Evanchik M.S.
|
Chief Scientific Officer | -- | -- | 1973 |
|
Ms. Natalie Dement J.D.
|
VP & Head of Legal | -- | -- | -- |
|
Mr. Timothy Y. Zhou
|
Director of Corporate Development | -- | -- | -- |
|
Ms. Steph Palencia
|
Associate Director of Human Resources & Office Manager | -- | -- | -- |
|
Ms. Brittany de Temple
|
Senior Vice President of Development Operations | -- | -- | -- |
|
Dr. Emil M. deGoma M.D.
|
Chief Medical Officer | -- | -- | 1976 |
|
Mr. Tyler Chavez Ph.D.
|
Chief Business Officer | -- | -- | 1989 |
Braveheart Bio, Inc.
One Letterman Drive
Building A Suite A4-300
San Francisco, CA 94129
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 49
Description
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Corporate Governance
Braveheart Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Braveheart Bio, Inc. Earnings Date
